GVHDS
MCID: GRF003
MIFTS: 71

Graft-Versus-Host Disease (GVHDS)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Graft-Versus-Host Disease

MalaCards integrated aliases for Graft-Versus-Host Disease:

Name: Graft-Versus-Host Disease 57 36 54 37
Graft-Versus-Host Disease, Susceptibility to 57 29 39
Graft Versus Host Disease 73 58 54
Graft-Versus-Host Disease, Protection Against 57 13
Graft-Vs-Host Disease 70
Gvhds 57
Gvh 58

Characteristics:

Orphanet epidemiological data:

58
graft versus host disease
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare immunological diseases


Summaries for Graft-Versus-Host Disease

OMIM® : 57 Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow precursors, such as certain leukemias and lymphomas, and it can be used to cure some primary immunodeficiencies and inherited hematopoietic stem-cell diseases. One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease (GVHD), in which mature donor T cells that contaminate the allogeneic bone marrow recognize the tissues of the recipient as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease. GVHD is particularly virulent when there is a mismatch of a major major histocompatibility complex (MHC) class I or class II antigen. Most transplants are therefore undertaken only when the donor and recipient are HLA-matched sibs or, less frequently, when there is an HLA-matched unrelated donor. However, GVHD also occurs in the context of disparities between minor histocompatibility antigens, and immunosuppression must be used in every stem-cell transplant (summary by Janeway et al., 2005). At the core of the immunogenetic basis for GVHD is the diversity of HLA, killer immunoglobulin-like receptors (KIRs; see 604936), and cytokine genes. HLA class I molecules function as ligands for natural killer cell inhibitory KIRs, indicating that GVHD results from a complex interplay between innate and adaptive immune responses. Cytokines may modulate the intensity of tissue injury and inflammation in GVHD, and therefore cytokine polymorphisms in either patient or donor or both may explain individual risks of GVHD (review by Petersdorf and Malkki, 2006). (614395) (Updated 05-Apr-2021)

MalaCards based summary : Graft-Versus-Host Disease, also known as graft-versus-host disease, susceptibility to, is related to chronic graft versus host disease and acute graft versus host disease. An important gene associated with Graft-Versus-Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Graft-versus-host disease and Innate Immune System. The drugs Lomustine and Panobinostat have been mentioned in the context of this disorder. Affiliated tissues include Bone, bone marrow and t cells, and related phenotypes are elevated hepatic transaminase and skin erosion

KEGG : 36 Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.

Wikipedia : 73 Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. GvHD... more...

Related Diseases for Graft-Versus-Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Graft-Versus-Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1137)
# Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 33.6 IL1A IL10 IFNG
2 acute graft versus host disease 32.5 TNF IL2 IL10 IFNG FASLG ARHGAP45
3 bronchiolitis obliterans 32.2 TNF IL6 IL10 IFNG GZMB
4 systemic scleroderma 31.8 TNF IL6 IL10 IFNG
5 severe combined immunodeficiency 31.6 IL6 IL2 IL10 IFNG
6 mucositis 31.5 IL2 IL1B IL10
7 exanthem 31.5 TNF IL6 IL2 IL1B IL10 IFNG
8 bronchiolitis 31.4 TNF IL6 IL1B IL10 IFNG
9 keratoconjunctivitis 31.4 TNF IL6 IL2 IFNG
10 hemorrhagic cystitis 31.4 TNF IL2 HLA-A
11 fasciitis 31.3 TNF IL6 IL2 IFNG
12 stevens-johnson syndrome/toxic epidermal necrolysis 31.3 HLA-C HLA-B HLA-A
13 diarrhea 31.2 TNF IL6 IL2 IL1B IL10 IFNG
14 localized scleroderma 31.2 TNF IL6 IL2
15 cystitis 31.2 TNF IL6 IL2 IL1A
16 post-transplant lymphoproliferative disease 31.0 TNF IL6 IL1A IL10
17 pemphigoid 31.0 TNF IFNG HLA-DRB1 HLA-DQB1
18 enterocolitis 31.0 TNF IL6 IL10
19 chickenpox 31.0 TNF IL6 IL2 IL10 IFNG
20 bilirubin metabolic disorder 30.9 TNF IL6 IL2 IL1B
21 conjunctivitis 30.9 TNF IL6 IL2 IL10 IFNG HLA-B
22 bronchitis 30.9 TNF IL6 IL1B IL10
23 purpura 30.9 TNF IL6 IL10 IFNG
24 vitiligo-associated multiple autoimmune disease susceptibility 1 30.9 TNF IL2 HLA-B
25 keratitis, hereditary 30.8 TNF IL6 IL1B IL1A IL10
26 chronic inflammatory demyelinating polyradiculoneuropathy 30.8 IL10 IFNG HLA-DRB1
27 gastritis 30.8 TNF IL6 IL1B IL10
28 frontal fibrosing alopecia 30.8 HLA-B HLA-A
29 cholangitis 30.7 TNF IL6 IL2 IL10 HLA-DRB1 HLA-B
30 sialadenitis 30.7 TNF HLA-DQB1 CD28
31 respiratory failure 30.7 TNF IL6 IL1B IL1A IL10
32 cutaneous t cell lymphoma 30.7 IL2 IFNG GZMB FAS
33 pneumonia 30.7 TNF IL6 IL1B IL10 IFNG
34 disseminated intravascular coagulation 30.7 TNF IL6 IL10
35 encephalitis 30.7 TNF IL6 IL1B IL10
36 human cytomegalovirus infection 30.7 IL6 IL1B HLA-C HLA-A FAS
37 retinal detachment 30.7 TNF IL6 IL10 IFNG
38 aspergillosis 30.7 TNF IL6 IL1B IL1A IL10 IFNG
39 lichen planus 30.7 TNF IL6 IL2 IL1B IL10 IFNG
40 bacterial pneumonia 30.7 TNF IL6 IL1B IL10
41 calcinosis 30.6 TNF HLA-DRB1 HLA-DQB1
42 peritonitis 30.6 TNF IL6 IL1B IL10
43 myeloma, multiple 30.6 TNF IL6 IL2 IL1B IL10 CD28
44 acute pancreatitis 30.6 TNF IL6 IL1B IL10
45 gastroenteritis 30.6 TNF IL6 IL1B IL10 IFNG
46 bacterial infectious disease 30.6 TNF IL6 IL1B IL1A IL10 IFNG
47 pure red-cell aplasia 30.6 IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
48 combined immunodeficiency 30.6 TNF IL6 IL2 IL1B IL10 IFNG
49 bacterial sepsis 30.6 TNF IL6 IL1B IL10
50 neutropenia 30.6 TNF IL6 IL2 IL1B IL10 FASLG

Graphical network of the top 20 diseases related to Graft-Versus-Host Disease:



Diseases related to Graft-Versus-Host Disease

Symptoms & Phenotypes for Graft-Versus-Host Disease

Human phenotypes related to Graft-Versus-Host Disease:

58 31 (show all 41)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 elevated hepatic transaminase 58 31 frequent (33%) Frequent (79-30%) HP:0002910
2 skin erosion 58 31 frequent (33%) Frequent (79-30%) HP:0200041
3 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
4 oral ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0000155
5 maculopapular exanthema 58 31 frequent (33%) Frequent (79-30%) HP:0040186
6 chronic hepatitis 58 31 frequent (33%) Frequent (79-30%) HP:0200123
7 stomatitis 58 31 frequent (33%) Frequent (79-30%) HP:0010280
8 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
9 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
10 skeletal muscle atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003202
11 gastrointestinal inflammation 58 31 occasional (7.5%) Occasional (29-5%) HP:0004386
12 irritability 58 31 occasional (7.5%) Occasional (29-5%) HP:0000737
13 jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0000952
14 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
15 limited elbow movement 58 31 occasional (7.5%) Occasional (29-5%) HP:0002996
16 inflammatory abnormality of the eye 58 31 occasional (7.5%) Occasional (29-5%) HP:0100533
17 hyperbilirubinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002904
18 tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001649
19 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
20 hepatosplenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001433
21 fasciitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100537
22 myositis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100614
23 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
24 hemophagocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012156
25 elevated alkaline phosphatase 58 31 occasional (7.5%) Occasional (29-5%) HP:0003155
26 scaling skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0040189
27 limited shoulder movement 58 31 occasional (7.5%) Occasional (29-5%) HP:0006467
28 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
29 acute hepatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0200119
30 recurrent gastroenteritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0031123
31 cutaneous sclerotic plaque 58 31 occasional (7.5%) Occasional (29-5%) HP:0031359
32 lichenoid skin lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0031452
33 failure to thrive 58 31 very rare (1%) Very rare (<4-1%) HP:0001508
34 lipodystrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0009125
35 trismus 58 31 very rare (1%) Very rare (<4-1%) HP:0000211
36 lymphadenopathy 58 31 very rare (1%) Very rare (<4-1%) HP:0002716
37 dupuytren contracture 58 31 very rare (1%) Very rare (<4-1%) HP:0005679
38 decreased lacrimation 58 31 very rare (1%) Very rare (<4-1%) HP:0000633
39 stiff interphalangeal joints 58 31 very rare (1%) Very rare (<4-1%) HP:0005198
40 recurrent infections 58 Frequent (79-30%)
41 inflammatory abnormality of the skin 58 Very frequent (99-80%)

Clinical features from OMIM®:

614395 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 10.25 HLA-A HLA-B HLA-C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 10.25 HLA-A HLA-B HLA-C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.25 HLA-C
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.25 HLA-A HLA-B HLA-C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 10.25 HLA-A HLA-B HLA-C
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.25 HLA-A HLA-B HLA-C
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 10.25 HLA-C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 10.25 HLA-A HLA-B HLA-C
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.25 HLA-A HLA-B HLA-C
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.25 HLA-C
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.25 HLA-C
12 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CD28 HLA-DQB1 IL2
13 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CD28 FAS FASLG GZMB IL10 IL1A
14 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.77 IL1A
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CD28 FAS GZMB IL10 IL1A IL1B
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CD28 FAS GZMB HLA-DQB1 IL10 IL1B

MGI Mouse Phenotypes related to Graft-Versus-Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.2 CENPF FAS FASLG HLA-DQB1 IFNG IL10
2 hematopoietic system MP:0005397 10.15 CD28 FAS FASLG HLA-A HLA-DQB1 IFNG
3 endocrine/exocrine gland MP:0005379 10.1 CD28 FAS FASLG HLA-A HLA-DQB1 IFNG
4 immune system MP:0005387 10.1 CD28 FAS FASLG HLA-A HLA-DQB1 IFNG
5 digestive/alimentary MP:0005381 10.09 CD28 FAS FASLG HLA-DQB1 IFNG IL10
6 integument MP:0010771 9.91 CD28 FAS FASLG IFNG IL10 IL1A
7 liver/biliary system MP:0005370 9.76 FAS FASLG HLA-DQB1 IFNG IL10 IL2
8 neoplasm MP:0002006 9.65 CD28 FAS FASLG IFNG IL10 IL1A
9 respiratory system MP:0005388 9.23 FAS FASLG HLA-DQB1 IFNG IL10 IL2

Drugs & Therapeutics for Graft-Versus-Host Disease

Drugs for Graft-Versus-Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 331)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
2
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
10
Semustine Experimental, Investigational Phase 4 13909-09-6
11 Antiparasitic Agents Phase 4
12 Antiprotozoal Agents Phase 4
13 Histone Deacetylase Inhibitors Phase 4
14 Antineoplastic Agents, Hormonal Phase 4
15 BB 1101 Phase 4
16 Anti-Infective Agents Phase 4
17 Antifungal Agents Phase 4
18 Hormones Phase 4
19 Hormone Antagonists Phase 4
20 glucocorticoids Phase 4
21 Pharmaceutical Solutions Phase 4
22 Ophthalmic Solutions Phase 4
23 Anesthetics Phase 4
24 Lubricant Eye Drops Phase 4
25 Cytochrome P-450 CYP3A Inhibitors Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27
Hydroxyitraconazole Phase 4 108222
28
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
29
Budesonide Approved Phase 3 51333-22-3 63006 5281004
30
Hydroxychloroquine Approved Phase 3 118-42-3 3652
31
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
32
Morphine Approved, Investigational Phase 3 57-27-2 5288826
33
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
34
Clobetasol Approved, Experimental, Investigational Phase 3 25122-41-2, 25122-46-7 32798 5311051
35
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
36
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
37
Epirubicin Approved Phase 3 56420-45-2 41867
38
Mercaptopurine Approved Phase 3 50-44-2 667490
39
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
40
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
41
Lenograstim Approved, Investigational Phase 3 135968-09-1
42
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
43
rituximab Approved Phase 3 174722-31-7 10201696
44
Protein C Approved Phase 3
45
Abatacept Approved Phase 3 332348-12-6 10237
46
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
47
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
48
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
49
leucovorin Approved Phase 3 58-05-9 6006
50
Sodium citrate Approved, Investigational Phase 3 68-04-2

Interventional clinical trials:

(show top 50) (show all 964)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
4 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
5 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
6 A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. Completed NCT00195481 Phase 4 Rapamune
7 A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
8 An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor Completed NCT00044720 Phase 4 Rapamune
9 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
10 A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune. Completed NCT00195468 Phase 4 CYCLOSPORINE
11 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Completed NCT01856803 Phase 4 anti thymoglobulin
12 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil;Ciclosporin A (CsA);methotrexate (MTX)
13 ATG Used in Allogeneic Hematopoietic Stem Cell Transplantation From HLA-matched Sibling Donor as GVHD Prophylaxis Recruiting NCT04203108 Phase 4 ATG;CsA;MTX;MMF
14 Shanghai General Hospital Affiliated to Shanghai Jiao Tong University Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
15 Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft-versus- Host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT04778618 Phase 4 Antithymocyte Globulin
16 Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Recruiting NCT02386800 Phase 4 ruxolitinib tablets or oral pediatric formulation, panobinostat capsules;ruxolitinib tablets or oral pediatric formulation
17 Ikervis for Prophylaxis of Dry Eye Disease Due to Graft vs Host Disease Post Allogeneic Haemtopoietic Stem Cell Transplant Recruiting NCT04636918 Phase 4 Cyclosporine Ophthalmic
18 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
19 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
20 Evaluation of Dextenza in Patients With Ocular Graft Vs Host Disease (GVHD) and Effect on Ocular Surface Disease Outcomes. Not yet recruiting NCT04728646 Phase 4 DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
21 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
22 The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
23 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
24 Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors Unknown status NCT03066466 Phase 3 Atorvastatin;Methotrexate;Tacrolimus
25 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
26 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
27 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Unknown status NCT02291770 Phase 3
28 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
29 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
30 Comparing ATG-Fresenius vs Thymoglobulin for the Prevention of Graft-versus-host Disease in the Setting of Haplo-identical Hematopoietic Stem Cell Transplantation Unknown status NCT03631563 Phase 2, Phase 3 Immunosuppressive Agent
31 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
32 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
33 A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission Unknown status NCT01067300 Phase 3
34 TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia Unknown status NCT00914628 Phase 3
35 Evaluation of a Donor Testing Kit for the Prediction of Acute GVHD in Patient Receiving a Peripheral Blood Stem Cells Allograft- Predictor 2 Unknown status NCT03887156 Phase 2, Phase 3
36 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
37 A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
38 Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
39 Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3 Budesonide
40 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
41 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
42 A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms Completed NCT00043147 Phase 3 beclomethasone dipropionate;methylprednisolone;prednisone
43 Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
44 Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo Completed NCT00053976 Phase 3 methylprednisolone;Placebo
45 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
46 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
47 Compare the Safety and Effective of HLA-mismatched Microtransplantation With HLA-matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-risk Completed NCT02461121 Phase 3 cyclosporine A;Mycophenolate mofetil;Ara-C;fludarabine;anti-lymphocyte globulin;cyclophosphamide
48 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
49 Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT03106662 Phase 3 cyclophosphamide administration
50 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3

Search NIH Clinical Center for Graft-Versus-Host Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Daclizumab
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Muromonab-CD3
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Prednisone
PREDNISONE PWDR
Tacrolimus
Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Graft-Versus-Host Disease cell therapies at LifeMap Discovery.

Genetic Tests for Graft-Versus-Host Disease

Genetic tests related to Graft-Versus-Host Disease:

# Genetic test Affiliating Genes
1 Graft-Versus-Host Disease, Susceptibility to 29 IL10

Anatomical Context for Graft-Versus-Host Disease

MalaCards organs/tissues related to Graft-Versus-Host Disease:

40
Bone Marrow, Bone, T Cells, Myeloid, Skin, Eye, Nk Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Graft-Versus-Host Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Graft-Versus-Host Disease

Articles related to Graft-Versus-Host Disease:

(show top 50) (show all 22701)
# Title Authors PMID Year
1
Genetics of risk factors for graft-versus-host disease. 61 57 54
16412785 2006
2
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. 57 54 61
14657427 2003
3
A protective gene for graft-versus-host disease. 61 57
14657422 2003
4
Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. 57
9162098 1997
5
Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. 54 61
19965675 2010
6
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. 61 54
20160060 2010
7
Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. 61 54
20025985 2010
8
Soluble lymphotoxin is an important effector molecule in GVHD and GVL. 61 54
19789388 2010
9
CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease. 61 54
20053336 2010
10
Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. 54 61
19462221 2009
11
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. 61 54
19159415 2009
12
Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. 54 61
19409109 2009
13
Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. 61 54
19221040 2009
14
Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. 61 54
19260829 2009
15
Donor treatment with a multipegylated G-CSF maximizes graft-versus-leukemia effects. 61 54
19135951 2009
16
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. 61 54
18614760 2008
17
Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. 61 54
18541194 2008
18
Interleukin-10 gene polymorphism in bone marrow transplant recipients. 54 61
18405249 2008
19
Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients. 61 54
18234053 2008
20
[Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]. 54 61
18681305 2008
21
PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. 54 61
18301339 2008
22
Importance of interleukin-7 in the development of experimental graft-versus-host disease. 54 61
18158957 2008
23
IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. 54 61
18021367 2007
24
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. 61 54
17889355 2007
25
Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. 61 54
17984846 2007
26
Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. 61 54
17429441 2007
27
Granulocyte colony-stimulating factor for the induction of T-cell tolerance. 54 61
17632408 2007
28
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. 61 54
17496542 2007
29
Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. 61 54
17331846 2007
30
Expression of CCR5 in graft-versus-host disease (GVHD) of the skin: immunohistochemical staining of 38 cases. 61 54
17352723 2007
31
Interleukin-18 and the pathogenesis of inflammatory diseases. 54 61
17336692 2007
32
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. 54 61
16937391 2007
33
CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 61 54
17145599 2006
34
Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. 54 61
16984283 2006
35
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. 54 61
16864058 2006
36
Effect of interleukin-15 on alloreactivity in umbilical cord blood. 61 54
16860714 2006
37
DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. 54 61
16707472 2006
38
No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. 61 54
16646673 2006
39
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. 54 61
16123384 2006
40
Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis. 54 61
16367941 2006
41
Genomic polymorphism and allogeneic hematopoietic transplantation outcome. 61 54
16399580 2006
42
Daclizumab for children with corticosteroid refractory graft-versus-host disease. 54 61
16247417 2006
43
Cytokine-mediated signalling and early defects in lymphoid development. 61 54
16264332 2005
44
Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation. 54 61
16344675 2005
45
Interleukin-18 treatment options for inflammatory diseases. 54 61
20477603 2005
46
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. 54 61
15976176 2005
47
The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. 54 61
16219576 2005
48
Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. 54 61
16125641 2005
49
Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution. 54 61
15778730 2005
50
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. 61 54
15591118 2005

Variations for Graft-Versus-Host Disease

Copy number variations for Graft-Versus-Host Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 188553 4 66300000 70400000 Absence of gene UGT2B17 Graft versus host disease

Expression for Graft-Versus-Host Disease

Search GEO for disease gene expression data for Graft-Versus-Host Disease.

Pathways for Graft-Versus-Host Disease

Pathways related to Graft-Versus-Host Disease according to KEGG:

36
# Name Kegg Source Accession
1 Graft-versus-host disease hsa05332

Pathways related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 TNF IL6 IL2 IL1B IL1A IL10
2
Show member pathways
13.89 TNF IL6 IL2 IL1B IL1A IL10
3
Show member pathways
13.77 TNF IL6 IL2 IL1B IL1A IL10
4
Show member pathways
13.52 TNF IL6 IL2 IL1B IL1A IL10
5
Show member pathways
13.45 TNF IL6 IL1B IL1A GZMB FASLG
6
Show member pathways
13.43 TNF IL6 IL2 IL1B IL1A IL10
7
Show member pathways
13.42 TNF IL6 IL2 IL1B IL1A IL10
8
Show member pathways
13.32 TNF IL6 IL2 IL1B IL10 IFNG
9
Show member pathways
13.29 TNF IL2 IL1B IL1A IFNG HLA-DRB1
10
Show member pathways
13.13 TNF IL6 IL2 HLA-C HLA-B HLA-A
11
Show member pathways
13.09 TNF IL6 IL1B HLA-C HLA-B HLA-A
12
Show member pathways
13.01 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
13 12.9 IL6 IL2 IFNG FASLG FAS
14 12.83 TNF IL1B IL1A FASLG FAS
15
Show member pathways
12.81 TNF IL6 IL1B FASLG FAS
16
Show member pathways
12.81 TNF IL2 IL10 IFNG HLA-DRB1 HLA-DQB1
17
Show member pathways
12.8 TNF IL1B IL1A IFNG FASLG FAS
18 12.8 TNF IL6 IL1B IFNG HLA-DRB1 HLA-DQB1
19
Show member pathways
12.78 TNF IL6 IL2 IL1B IL1A
20
Show member pathways
12.78 TNF IL6 IL2 IL1B IL1A IL10
21
Show member pathways
12.73 TNF IL6 IL2 IL1B IL10 IFNG
22 12.73 TNF IL2 IL1B IL10 IFNG GZMB
23
Show member pathways
12.7 IFNG HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B
24
Show member pathways
12.68 TNF IL1B IL1A FASLG FAS
25
Show member pathways
12.67 TNF IL2 IFNG HLA-C HLA-B HLA-A
26
Show member pathways
12.65 TNF IL6 IL2 IL1B IL1A IL10
27
Show member pathways
12.54 TNF IL6 IL2 IL1B IL1A IFNG
28 12.5 TNF IL6 IL2 HLA-DRB1 HLA-DQB1 HLA-DPB1
29
Show member pathways
12.47 IL6 IL2 IL10 IFNG
30
Show member pathways
12.46 TNF IL6 IL2 IL1B IFNG
31
Show member pathways
12.45 IL2 HLA-DRB1 HLA-DQB1 CD28
32
Show member pathways
12.43 TNF IL6 IL1B IL1A IFNG
33
Show member pathways
12.43 TNF IL1B IL1A IL10 IFNG HLA-DRB1
34
Show member pathways
12.4 TNF IL6 IL1B IFNG
35
Show member pathways
12.4 TNF IL6 IL2 IL10
36
Show member pathways
12.4 TNF IL6 IL2 IL1B IL1A IL10
37
Show member pathways
12.38 TNF IL1B IL1A IFNG FASLG FAS
38
Show member pathways
12.37 TNF IL1A GZMB FASLG FAS
39
Show member pathways
12.37 TNF IL6 IL1B IFNG FASLG FAS
40 12.37 TNF IL6 IL1B IL1A IL10 IFNG
41
Show member pathways
12.35 TNF IL6 IL2 IL1B IL10
42 12.33 TNF GZMB FASLG FAS
43 12.33 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
44 12.32 TNF IL6 IL1B IL1A IL10
45 12.32 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
46
Show member pathways
12.3 HLA-DRB1 HLA-DQB1 HLA-DPB1 CD28
47 12.3 IL6 IL1A HLA-C HLA-B HLA-A
48
Show member pathways
12.29 TNF IL6 IL2 IL1B IL1A IL10
49 12.24 TNF IL6 IL2 IL1B IL10
50 12.21 TNF IL6 IL2 IL1B IL1A IFNG

GO Terms for Graft-Versus-Host Disease

Cellular components related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.09 TNF IL6 IL2 IL1B IL1A IL10
2 extracellular region GO:0005576 10.06 TNF IL6 IL2 IL1B IL1A IL10
3 Golgi membrane GO:0000139 9.95 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
4 lysosome GO:0005764 9.92 IL1B HLA-DRB1 HLA-DQB1 HLA-DPB1 FASLG
5 external side of plasma membrane GO:0009897 9.91 TNF HLA-DRB1 FASLG FAS CD28
6 cell surface GO:0009986 9.81 TNF HLA-DRB1 HLA-DPB1 HLA-C HLA-B HLA-A
7 recycling endosome membrane GO:0055038 9.73 HLA-C HLA-B HLA-A
8 phagocytic vesicle membrane GO:0030670 9.72 HLA-C HLA-B HLA-A
9 endocytic vesicle membrane GO:0030666 9.71 HLA-DRB1 HLA-DQB1 HLA-DPB1
10 transport vesicle membrane GO:0030658 9.67 HLA-DRB1 HLA-DQB1 HLA-DPB1
11 immunological synapse GO:0001772 9.63 HLA-DRB1 GZMB CD28
12 clathrin-coated endocytic vesicle membrane GO:0030669 9.58 HLA-DRB1 HLA-DQB1 HLA-DPB1
13 MHC class II protein complex GO:0042613 9.54 HLA-DRB1 HLA-DQB1 HLA-DPB1
14 MHC class I protein complex GO:0042612 9.43 HLA-C HLA-B HLA-A
15 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
16 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A

Biological processes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.21 IL2 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B
2 apoptotic process GO:0006915 10.19 IL1B IL1A IFNG GZMB FASLG FAS
3 positive regulation of gene expression GO:0010628 10.15 TNF IL6 IL1B IL1A IFNG CD28
4 negative regulation of apoptotic process GO:0043066 10.14 IL6 IL2 IL10 FAS CD28
5 T cell receptor signaling pathway GO:0050852 10 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-A CD28
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.99 TNF IL6 IL1B IL10
7 cellular response to lipopolysaccharide GO:0071222 9.99 TNF IL6 IL1B IL1A IL10
8 positive regulation of inflammatory response GO:0050729 9.95 TNF IL2 IL1B IFNG
9 positive regulation of protein phosphorylation GO:0001934 9.95 TNF IL2 IL1B IFNG HLA-DRB1 FAS
10 regulation of insulin secretion GO:0050796 9.94 TNF IL6 IL1B IFNG
11 positive regulation of tumor necrosis factor production GO:0032760 9.92 IL6 IL1A IFNG
12 apoptotic signaling pathway GO:0097190 9.92 TNF FASLG FAS CD28
13 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.91 HLA-C HLA-B HLA-A
14 type I interferon signaling pathway GO:0060337 9.91 HLA-C HLA-B HLA-A
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL6 IL2 IFNG
16 cytokine-mediated signaling pathway GO:0019221 9.91 TNF IL6 IL2 IL1B IL1A IL10
17 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
18 positive regulation of interleukin-8 production GO:0032757 9.9 TNF IL6 IL1B
19 positive regulation of interleukin-1 beta production GO:0032731 9.9 TNF IL6 IFNG
20 positive regulation of phagocytosis GO:0050766 9.89 TNF IL1B IFNG
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.89 TNF IL1B IFNG
22 positive regulation of chemokine production GO:0032722 9.88 TNF IL6 IFNG
23 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.88 TNF IL1B IL1A
24 positive regulation of JAK-STAT cascade GO:0046427 9.87 TNF IL6 IL10
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.87 IL2 IL1A FAS
26 humoral immune response GO:0006959 9.87 TNF IL6 IFNG CD28
27 positive regulation of interleukin-2 production GO:0032743 9.86 IL1B IL1A CD28
28 positive regulation of mitotic nuclear division GO:0045840 9.86 IL1B IL1A CD28
29 positive regulation of cytokine production GO:0001819 9.86 TNF IL1A IL10 IFNG
30 adaptive immune response GO:0002250 9.86 IL2 IFNG HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C
31 positive regulation of vascular endothelial growth factor production GO:0010575 9.85 IL6 IL1B IL1A
32 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.85 HLA-C HLA-B HLA-A
33 positive regulation of interleukin-6 production GO:0032755 9.85 TNF IL6 IL1B IL1A IFNG
34 extrinsic apoptotic signaling pathway GO:0097191 9.84 TNF IFNG FASLG FAS
35 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
36 positive regulation of T cell mediated cytotoxicity GO:0001916 9.83 HLA-DRB1 HLA-B HLA-A
37 positive regulation of immunoglobulin production GO:0002639 9.82 IL6 IL2 IL10
38 positive regulation of glial cell proliferation GO:0060252 9.82 TNF IL6 IL1B
39 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.81 TNF IL1B IFNG
40 regulation of regulatory T cell differentiation GO:0045589 9.8 IL2 IFNG CD28
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.8 TNF IL1B IL10
42 positive regulation of interferon-gamma production GO:0032729 9.8 TNF IL2 IL1B HLA-DPB1 HLA-A
43 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.77 HLA-DRB1 HLA-DQB1 HLA-DPB1
44 positive regulation of neuroinflammatory response GO:0150078 9.76 TNF IL6 IL1B
45 detection of bacterium GO:0016045 9.75 HLA-DRB1 HLA-B HLA-A
46 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
47 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 IL10 IFNG
48 regulation of establishment of endothelial barrier GO:1903140 9.74 TNF IL1B
49 positive regulation of isotype switching to IgG isotypes GO:0048304 9.74 IL2 CD28
50 negative regulation of lipid storage GO:0010888 9.73 TNF IL6

Molecular functions related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 TNF IL6 IL2 IL1B IL1A IL10
2 cytokine activity GO:0005125 9.56 TNF IL6 IL2 IL1B IL1A IL10
3 T cell receptor binding GO:0042608 9.37 HLA-DRB1 HLA-A
4 TAP binding GO:0046977 9.33 HLA-C HLA-B HLA-A
5 MHC class II receptor activity GO:0032395 9.32 HLA-DRB1 HLA-DQB1
6 peptide antigen binding GO:0042605 9.1 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A

Sources for Graft-Versus-Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....